Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 12:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 528 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pharmacokinetic Study in Healthy Volunteers Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetics and Safety of Methylphenidate HCl in Healthy Japanese Adult Male Volunteers

NCT01202734
View directory record Official record
Conditions
Healthy
Interventions
Methylphenidate HCl
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
20 Years to 35 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 10, 2026, 12:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetics Study Comparing PF-06438179 and Infliximab in Healthy Volunteers (REFLECTIONS B537-01)

NCT01844804
View directory record Official record
Conditions
Healthy
Interventions
PF-06438179, Remicade
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Oct 10, 2026, 12:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A PK Study of IkT-148009 in Older and Elderly Healthy Subjects

NCT06644326
View directory record Official record
Conditions
Healthy
Interventions
100mg IkT-148009 Wet, 200 mg Itraconazole, 100mg IkT-148009 Dry, 50mg IkT-148009 Wet
Drug
Lead sponsor
ABLi Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 10, 2026, 12:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioavailability and Pharmacokinetic Parameters of Watermelon (Rind, Flesh and Seeds) Polyphenols

NCT03365960
View directory record Official record
Conditions
Healthy Subjects
Interventions
Watermelon Rind, Watermelon Flesh, Watermelon Seeds, Placebo
Dietary Supplement
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
20 Years to 45 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 10, 2026, 12:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.

NCT05078580
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Iptacopan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 10, 2026, 12:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Drug-Drug Interaction Study Between K-877 and CSG452 in Healthy Adult Volunteers

NCT04237597
View directory record Official record
Conditions
Healthy
Interventions
K-877, CSG452
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 10, 2026, 12:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS

NCT01255709
View directory record Official record
Conditions
Asthma
Interventions
Arm T1: Primatene Mist HFA, Arm T2: Primatene Mist HFA, Arm C: Primatene Mist (epinephrine inhalation aerosol, USP)
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 30 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 10, 2026, 12:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis

NCT02620787
View directory record Official record
Conditions
Diabetes, Wound Infection, Healthy Volunteers
Interventions
Tedizolid, Microdialysis Catheter Insertion
Drug · Procedure
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 10, 2026, 12:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers

NCT01087749
View directory record Official record
Conditions
Kidney Disease
Interventions
Propranolol, Losartan, Eprosartan
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 10, 2026, 12:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination

NCT02684799
View directory record Official record
Conditions
Healthy
Interventions
Cenicriviroc, Omeprazole, Famotidine
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 10, 2026, 12:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants

NCT06719128
View directory record Official record
Conditions
Hepatic Insufficiency, Healthy
Interventions
Olomorasib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
Lake Forest, California • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 10, 2026, 12:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3478045 in Healthy Participants

NCT04270370
View directory record Official record
Conditions
Healthy
Interventions
LY3478045, Placebo, Atorvastatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Oct 10, 2026, 12:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Dose of GV101 in Healthy Subjects

NCT05068947
View directory record Official record
Conditions
Phase 1
Interventions
GV101, Placebo
Drug
Lead sponsor
Graviton Bioscience Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 10, 2026, 12:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of Omaveloxolone in Healthy Volunteers

NCT03664453
View directory record Official record
Conditions
Healthy
Interventions
omaveloxolone
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 10, 2026, 12:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone

NCT00862849
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Insulin Lispro, Regular Human Insulin, rHuPH20
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Oct 10, 2026, 12:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects

NCT05328726
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GZR-18, Placebo
Drug · Other
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 10, 2026, 12:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and Metoprolol

NCT02940379
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
sotagliflozin (SAR439954), midazolam, metoprolol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 10, 2026, 12:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years

NCT07455825
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5004
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 10, 2026, 12:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants

NCT06937619
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 60 Years
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
4
States / cities
Anaheim, California • Los Alamitos, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 10, 2026, 12:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

SAD Study to Evaluate Safety, Tolerability, and Pharmacokinetic Profile of AMN1126 in Healthy Post-Menopausal Females

NCT06467201
View directory record Official record
Conditions
Healthy Postmenopausal Women
Interventions
KSHN001126 150mg, KSHN001126 300mg, KSHN001126 600mg
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 10, 2026, 12:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic (PK) Study Evaluating Naproxen and Esomeprazole Plasma Levels

NCT00749385
View directory record Official record
Conditions
Arthritis
Interventions
PN 400, EC naproxen plus EC esomeprazole, EC naproxen, EC esomeprazole
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 23, 2008 · Synced Oct 10, 2026, 12:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants

NCT04147338
View directory record Official record
Conditions
Healthy
Interventions
Guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 10, 2026, 12:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study in Adult Healthy Volunteers to Assess QD Dosing With the Selected Age-appropriate MR Formulations

NCT03112148
View directory record Official record
Conditions
Healthy
Interventions
10 mg dose MR formulations,10 mg dose of tofacitinib IR solution
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 10, 2026, 12:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Diindolylmethane in Healthy Volunteers

NCT00392652
View directory record Official record
Conditions
Healthy, no Evidence of Disease
Interventions
oral microencapsulated diindolylmethane
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 10, 2026, 12:06 AM EDT